Unknown

Dataset Information

0

A plug-and-play monofunctional platform for targeted degradation of extracellular proteins and vesicles.


ABSTRACT: Existing strategies use bifunctional chimaeras to mediate extracellular protein degradation. However, these strategies rely on specific lysosome-trafficking receptors to facilitate lysosomal delivery, which may raise resistance concerns due to intrinsic cell-to-cell variation in receptor expression and mutations or downregulation of the receptors. Another challenge is establishing a universal platform applicable in multiple scenarios. Here, we develop MONOTAB (MOdified NanOparticle with TArgeting Binders), a plug-and-play monofunctional degradation platform that can drag extracellular targets into lysosomes for degradation. MONOTAB harnesses the inherent lysosome-targeting ability of certain nanoparticles to obviate specific receptor dependency and the hook effect. To achieve high modularity and programmable target specificity, we utilize the streptavidin-biotin interaction to immobilize antibodies or other targeting molecules on nanoparticles, through an antibody mounting approach or by direct binding. Our study reveals that MONOTAB can induce efficient degradation of diverse therapeutic targets, including membrane proteins, secreted proteins, and even extracellular vesicles.

SUBMITTER: Yao S 

PROVIDER: S-EPMC11341853 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

A plug-and-play monofunctional platform for targeted degradation of extracellular proteins and vesicles.

Yao Shasha S   Wang Yi Y   Tang Qian Q   Yin Yujie Y   Geng Yu Y   Xu Lei L   Liang Shifu S   Xiang Jiajia J   Fan Jiaqi J   Tang Jianbin J   Liu Jian J   Shao Shiqun S   Shen Youqing Y  

Nature communications 20240822 1


Existing strategies use bifunctional chimaeras to mediate extracellular protein degradation. However, these strategies rely on specific lysosome-trafficking receptors to facilitate lysosomal delivery, which may raise resistance concerns due to intrinsic cell-to-cell variation in receptor expression and mutations or downregulation of the receptors. Another challenge is establishing a universal platform applicable in multiple scenarios. Here, we develop MONOTAB (MOdified NanOparticle with TArgetin  ...[more]

Similar Datasets

| S-EPMC5795695 | biostudies-literature
| S-EPMC4992066 | biostudies-literature
| S-EPMC8953635 | biostudies-literature
2021-02-10 | GSE120673 | GEO
| S-EPMC8319308 | biostudies-literature
| S-EPMC10203435 | biostudies-literature
| S-EPMC10160774 | biostudies-literature
| S-EPMC8762996 | biostudies-literature
| S-EPMC8092002 | biostudies-literature
| S-EPMC5399599 | biostudies-literature